UBS Group
SGMT icon

UBS Group’s Sagimet Biosciences SGMT Stock Holding History

UBS Group’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.54M Buy
293,934
+92,175
+46% +$514K ﹤0.01% 5204
2025
Q4 		$1.19M Sell
201,759
-105,007
-34% -$754K ﹤0.01% 5423
2025
Q3 		$2.1M Sell
306,766
-265,969
-46% -$2.16M ﹤0.01% 4895
2025
Q2 		$4.36M Buy
572,735
+94,305
+20% +$398K ﹤0.01% 4026
2025
Q1 		$1.56M Buy
478,430
+145,270
+44% +$609K ﹤0.01% 4908
2024
Q4 		$1.5M Buy
333,160
+191,895
+136% +$972K ﹤0.01% 4983
2024
Q3 		$391K Buy
141,265
+44,893
+47% +$138K ﹤0.01% 5399
2024
Q2 		$330K Buy
96,372
+33,236
+53% +$152K ﹤0.01% 5312
2024
Q1 		$342K Buy
63,136
+43,148
+216% +$310K ﹤0.01% 5475
2023
Q4 		$108K Buy
19,988
+16,997
+568% +$80.2K ﹤0.01% 6127
2023
Q3 		$26.3K Buy
+2,991
New +$39.8K ﹤0.01% 6660

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group's SGMT Position: Q1 2026 in Review

UBS Group increased its Sagimet Biosciences (SGMT) stake by 46% in Q1 2026, buying an estimated $514K and bringing the position to 293,934 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #5204.

UBS Group first reported a position in SGMT in Q3 2023 and has held it in 11 quarters since. The position peaked at $4.36M in Q2 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • UBS Group held 293,934 shares of Sagimet Biosciences worth $1.54M as of Q1 2026.
  • UBS Group bought 92,175 Sagimet Biosciences shares in Q1 2026, an estimated $514K.
  • Sagimet Biosciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5204 holding.
  • UBS Group first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 11 quarters since.
  • UBS Group's Sagimet Biosciences position peaked at $4.36M in Q2 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.